This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis (BIANCA-SC)

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
Anthera Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01598857
First received: May 11, 2012
Last updated: July 28, 2015
Last verified: July 2015
  Purpose
The purpose of this study is to evaluate efficacy, safety and tolerability of blisibimod when taken with methotrexate in the induction of remission in ANCA-Associated Small Vessel Vasculitis.

Condition Intervention Phase
Granulomatosis With Polyangiitis Microscopic Polyangiitis Drug: Blisibimod Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis

Resource links provided by NLM:


Further study details as provided by Anthera Pharmaceuticals:

Primary Outcome Measures:
  • Induction of clinical remission [ Time Frame: 24 weeks ]
    Clinical remission includes the ability to taper corticosteroids.


Secondary Outcome Measures:
  • Time to complete remission [ Time Frame: Various timepoints to 24 weeks ]
  • Time to treatment failure [ Time Frame: Various timepoints to 24 weeks ]
  • Ability to taper corticosteroids [ Time Frame: Various timepoints to 24 weeks ]
  • Change in baseline BVAS/WG score [ Time Frame: Various timepoints to 24 weeks ]
  • Safety profile [ Time Frame: Various timepoints to 24 weeks ]
  • Compare biomarker changes from baseline [ Time Frame: Various timepoints to 24 weeks ]

Enrollment: 0
Study Start Date: December 2014
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Blisibimod Drug: Blisibimod
Placebo Comparator: Placebo Drug: Placebo

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 18 years of age or older (male or female).
  2. Granulomatosis with polyangiitis (GPA, or Wegener's granulomatosis) or microscopic polyangiitis (MPA) according to the definitions of the American College of Rheumatology and Chapel Hill Consensus Conference.
  3. Active GPA or MPA disease at screening.
  4. Positive for either PR3-ANCA or MPO-ANCA at screening.
  5. Subject willing to initiate corticosteroids and methotrexate (MTX) if not already on corticosteroids and/or MTX at baseline.
  6. Clinical intention to prescribe MTX therapy for treatment of GPA or MPA.

Exclusion Criteria:

  1. Diagnosed with Churg Strauss syndrome.
  2. Severe GPA or MPA disease that would conventionally be treated with cyclophosphamide.
  3. Nursing or pregnant.
  4. Active systemic infection or deep-space infection.
  5. Active hepatitis B, active hepatitis C or a documented history of HIV, hepatitis B, or hepatitis C.
  6. Liver disease.
  7. History of documented anti-glomerular basement membrane (GBM) disease.
  8. Malignancy within the past 5 years.
  9. History of active tuberculosis (TB) or history of TB infection.
  10. Anemia, neutropenia, or thrombocytopenia.
  11. Serum creatinine level greater than 2.5 mg/dL.
  12. Prior administration of a B-cell modulating therapy other than rituximab.
  13. Subject has not yet completed at least 3 months or 5 half-lives (whichever is longer) since ending other investigational study.
  14. History of congenital immunodeficiency.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Anthera Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01598857     History of Changes
Other Study ID Numbers: AN-VAS3321
Study First Received: May 11, 2012
Last Updated: July 28, 2015

Keywords provided by Anthera Pharmaceuticals:
granulomatosis with polyangiitis
microscopic polyangiitis
anti-neutrophil cytoplasmic antibodies
ANCA-associated vasculitis
Wegener Granulomatosis

Additional relevant MeSH terms:
Vasculitis
Systemic Vasculitis
Microscopic Polyangiitis
Granulomatosis with Polyangiitis
Vascular Diseases
Cardiovascular Diseases
Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Autoimmune Diseases
Immune System Diseases
Lung Diseases, Interstitial
Lung Diseases
Respiratory Tract Diseases
Methotrexate
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents

ClinicalTrials.gov processed this record on June 26, 2017